CD Genomics has launched Degradome Profiling and Ribo-Seq services, which enable researchers to obtain comprehensive insights into RNA degradation and translation initiation events, facilitating a better understanding of gene regulation and protein synthesis.
Shirley, New York, United States - May 6, 2023 —
CD Genomics’ RNA-Solutions is a platform for revolutionary research in RNA, targeting coding and non-coding RNAs with different physiological functions. Based on rich RNA project experience and leading bioinformatics analytical capabilities, CD Genomics has launched Degradome Profiling and Ribo-Seq services, which enable researchers to obtain comprehensive insights into RNA degradation and translation initiation events, facilitating a better understanding of gene regulation and protein synthesis.
CD Genomics’ Degradome Profiling service is based on advanced NGS technology, which enables the identification and quantification of RNA fragments generated by RNA degradation. This innovative technology can detect changes in RNA stability and degradation rates under different physiological or pathological conditions, making it an ideal tool for studying gene regulation, RNA turnover, and stress response.
Its Ribo-Seq service is based on ribosome footprinting technology, which enables the identification and quantification of RNA sequences that are actively translated by ribosomes. This powerful technique can help researchers identify ribosome pause sites, alternative translation initiation sites, and novel coding regions, providing a better understanding of translation regulation and identifying potential drug targets.
Both Degradome Profiling and Ribo-Seq services include sample preparation, library construction, and NGS sequencing, followed by comprehensive bioinformatic analysis and data interpretation by the company's experienced bioinformatics team. The company's state-of-the-art NGS sequencing technology and streamlined sample processing workflow ensure high-quality data with fast turnaround times.
“Our advanced Degradome Profiling and Ribo-Seq services provide researchers with cutting-edge tools to study RNA degradation and translation initiation events, offering a deeper understanding of gene regulation and protein synthesis,” said the Senior Scientist of CD Genomics. “These insights can help researchers identify novel targets for drug development and contribute to advances in the fields of molecular biology, genetics, and biotechnology.”
The two services offered by CD Genomics are highly flexible, allowing researchers to customize their experiments based on their specific research needs. The services can be used to study a wide range of organisms, including humans, animals, plants, and microorganisms, making them ideal for a broad range of applications, including drug discovery, functional genomics, and disease research.
“Our Degradome Profiling and Ribo-Seq are powerful tools for researchers to gain a deeper understanding of RNA degradation and translation initiation events. These insights can help researchers identify new drug targets, develop more effective therapies, and ultimately improve human health,” he further added.
About CD Genomics
CD Genomics enjoys a high reputation for sequencing, microarray analysis, library construction, and genotyping and provides reliable services to pharmaceutical and biotechnology companies, academic institutions, and government agencies.
Contact Info:
Name: Kiko Garcia
Email: Send Email
Organization: CD Genomics
Website: https://rna.cd-genomics.com/
Release ID: 89096935
If you detect any issues, problems, or errors in this press release content, kindly contact error@releasecontact.com to notify us. We will respond and rectify the situation in the next 8 hours.
